drugset / Trial / NCT06649656
A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors
NaSingle-groupOpen-labelTreatment
Summary
This study is a multicenter, single arm, and open design Phase I clinical trial aimed at evaluating the safety, Pharmacokinetics (PK) characteristics, immunogenicity, and preliminary efficacy of TQB2252 injection in subjects with advanced malignant tumors.
Timeline
- Start
- 2024-11
- Primary completion
- 2026-11
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Penpulimab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | TQB2223 | Monoclonal antibody | 600 mg | Intravenous |